Researchers who led a trial of Clovis Oncology Inc.’s experimental lung cancer drug, which is likely to be rejected next month by U.S. regulators, updated results from tests of the treatment after they said initial, promising data from the clinical trial were hurried out last year.
The drug’s actual response rate in patients with a form of non-small cell lung cancer was somewhere between the promising results that were released last April and disappointing data from November, said the researchers, led by Lecia Sequist, an oncologist at Massachusetts General Hospital. The updated findings were published Wednesday in a letter to the New England Journal of Medicine.
Read Full Article »